Immunotherapy for Metastatic Prostate Carcinoma

Emre YEKEDÜZa
aAnkara Etlik City Hospital, Clinic of Medical Oncology, Ankara, Türkiye

Yekedüz E. Immunotherapy for metastatic prostate carcinoma. In: Şendur MAN, ed. Current Immunotherapy Landscape for Solid Tumors. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.106-9.

ABSTRACT
Prostate cancer (PCa) is classified in the cold-tumors family and immunotherapy sensitivity is low. Up to now, no satisfying results have been obtained from the clinical trials about the use of immunotherapy in advanced PCa. Sipuleucel-T is an anti-cancer vaccine, including mature antigen-presenting cells cocultured with prostatic acid phosphatase (PAP) and granulocyte-macrophage colony-stimulating factor (GM-CSF). The Food and Drug Administration (FDA) approved it in the treatment of metastatic castration-resistant prostate cancer patients with asymptomatic or minimally symptomatic disease. Most clinical trials with immune checkpoint inhibitors (ICIs) have failed and promising data regarding the use of ICIs in advanced PCa is limited. Based on its tissue-agnostic approval by the FDA, pembrolizumab may be an option in advanced PCa patients with deficient miss match repair (dMMR)/microsatellite instability (MSI). However, it should be kept in mind that the number of patients with PCa was very low in the clinical trials, which led to these agents’ approval.

Keywords: Prostatic neoplasms; immunotherapy; cancer vaccines

Referanslar

  1. DePeaux K, Delgoffe GM. Metabolic barriers to cancer immunotherapy. Nat Rev Immunol. 2021;21(12):785-97. [Crossref]  [PubMed]  [PMC]
  2. Stultz J, Fong L. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):697-717. [Crossref]  [PubMed]  [PMC]
  3. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-22. [Crossref]  [PubMed]
  4. Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011; 17(11):3520-6. [Crossref]  [PubMed]
  5. Anassi E, Ndefo UA. Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. P T. 2011;36(4):197-202.
  6. Higano CS, Armstrong AJ, Sartor AO, Vogelzang NJ, Kantoff PW, McLeod DG, et al. Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. Cancer. 2019;125(23):4172-80. [Crossref]  [PubMed]  [PMC]
  7. Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, et al. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 2015; 21(17):3862-3869. [Crossref]  [PubMed]
  8. Petrylak DP, Drake CG, Pieczonka CM, Corman JM, Garcia JA, Dunshee C, et al. Overall survival and immune responses with sipuleucel-T and enzalutamide: STRIDE study. J Clin Oncol. 2018;36(6_suppl):246.doi: 10.1200/JCO.2018.36.6_suppl.246. [Crossref]
  9. Kantoff PW, Gulley JL, Pico-Navarro C. Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2017;35(1):124-5. [Crossref]  [PubMed]  [PMC]
  10. Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, et al. Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019;37(13):1051-61. [Crossref]  [PubMed]  [PMC]
  11. Vogelzang NJ, Beer TM, Gerritsen W, Oudard S, Wiechno P, Kukielka-Budny B, et al.; VIABLE Investigators. Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022;8(4):546-52. [Crossref]  [PubMed]  [PMC]
  12. Tateo V, Marchese PV, Mollica V, Massari F, Kurzrock R, Adashek JJ. Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. Pharmaceuticals (Basel). 2023;16(4):614. [Crossref]  [PubMed]  [PMC]
  13. Graham LS, Schweizer MT. Mismatch repair deficiency and clinical implications in prostate cancer. Prostate. 2022;82 Suppl 1:S37-S44. [Crossref]  [PubMed]
  14. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al.; CA184-043 Investigators. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700-12. [Crossref]  [PubMed]
  15. Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. J Clin Oncol. 2017;35(1):40-7. [Crossref]  [PubMed]
  16. Hansen AR, Massard C, Ott PA, Haas NB, Lopez JS, Ejadi S, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol. 2018;29(8):1807-13. [Crossref]  [PubMed]
  17. Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, et al. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. J Clin Oncol. 2020;38(5):395-405. [Crossref]  [PubMed]  [PMC]
  18. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54. [Crossref]  [PubMed]  [PMC]
  19. Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, et al. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell. 2020;38(4):489-99.e3. [Crossref]  [PubMed]
  20. Rebuzzi SE, Rescigno P, Catalano F, Mollica V, Vogl UM, Marandino L, et al. Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives. Cancers (Basel). 2022;14(5):1245. [Crossref]  [PubMed]  [PMC]
  21. Powles T, Yuen KC, Gillessen S, Kadel EE 3rd, Rathkopf D, Matsubara N, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. 2022;28(1):144-53. [Crossref]  [PubMed]  [PMC]
  22. Fizazi K, González Mella P, Castellano D, Minatta JN, Rezazadeh Kalebasty A, Shaffer D, et al. Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. Eur J Cancer. 2022;160:61-71. [Crossref]  [PubMed]
  23. Fizazi K, Retz M, Petrylak DP, Goh JC, Perez-Gracia J, Lacombe L, et al. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. J Immunother Cancer. 2022;10(8):e004761. [Crossref]  [PubMed]  [PMC]
  24. Antonarakis ES, Park SH, Goh JC, Shin SJ, Lee JL, Mehra N, et al. Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. J Clin Oncol. 2023;41(22):3839-50. [Crossref]  [PubMed]  [PMC]
  25. Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, et al. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol. 2022;23(7):899-909. [Crossref]  [PubMed]
  26. Cabozantinib/Atezolizumab Significantly Improves PFS in Metastatic CRPC. 2023 [Link]
  27. Antonarakis ES, Isaacsson Velho P, Fu W, Wang H, Agarwal N, Sacristan Santos V, et al. CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precis Oncol. 2020;4:370-81. [Crossref]  [PubMed]  [PMC]